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Abstract  
Background  The increasing  use of drug eluting stents in interventional 
cardiology  calls for assessment of their efficacy and safety, both among drug 
eluting and  bare-metal stents , in the context of rational decision making. 
Methods We searched for papers that compared any of the  sirolimus eluting 
stents, paclitaxel eluting stents, drug eluting stent , biodegradable stent, 
everolimus eluting stents, zotarolimus resolute eluting stent, biolimus eluting 
stent, bare metal Stent and  zotarolimus eluting stents. The search was 
contacted through Medline, the Cochrane database, Embase, TCTMD, 
ClinicalTrials.gov, Clinical Trial Results, CardioSource, abstracts and 
presentations from major cardiovascular meetings. We also searched for 
further articles cited by selected papers. Further, important conferences and 
relevant proceedings and abstracts, such as the American Heart Association, 
American College of Cardiology, Transcatheter Cardiovascular Therapeutics, 
Society of Cardiovascular Angiography and Intervention,  European Society of 
Cardiology, and Euro-PCR, were also searched. Inclusion criteria were : 
Randomised Controlled Trials (RCT), size of study ( ≥ 100 patients), duration 
more than 6 months and definition of reported endpoints  (Target Vessel 
Revascularization, Thrombosis, Myocardial Infarction and Cardiac death). 
Analysis of the data was performed for short term (less than a year) and long 
term(more than a year). A mixed treatment comparison approach was utilized 
for the data analysis.  
Conclusions  
 
Based on the rankings of each treatment, a distinct difference between 2nd 
and 1st generation stents was identified . We can conclude that everolimus, 
resolute and biolimus carry the highest probabilities of being superior for all 
endpoints.  
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1. Introduction  
Τhe introduction of percutaneous transluminal coronary angioplasty (PTCA) in 
1977 marked a new era in operational cardiology. A landmark year for 
operational cardiology was 1986, during which the introduction of the first 
stent in clinical practice by Puel and Sigwart [1], led to a fast uptake of this 
new technology . By 1999, stenting composed 84.2% of all Percutaneous 
Coronary Interventions (PCI) performed[2] .  
Although Bare Metal Stents (BMS) demonstrated a clear benefit, by reducing 
occurrence of acute mechanical complication of angioplasty and restenosis 
rates[3], stent thrombosis and late term restenosis still emerged as major 
challenges [4]. Neointimal hyperplasia, which on a cellular level is a reactive 
excessive growth of tissue around the stent, is exacerbated by BMS. Along 
with optimization of antiplatelet therapy and introduction of more potent 
agents, Drug Eluting Stents (DES) were developed in order to tackle the 
cellular reaction, by the sustained release of an antiproliferative (cytotoxic or 
cytostatic) substance from their surface, in order to limit cell growth. In 2003, 
sirolimus and paclitaxel eluting stents were introduced to clinical practice, 
demonstrating reduced need for revascularization and reduced angiographic 
late lumen loss compared to BMS[5], without proving significant superiority in 
mortality and myocardial infarction rates[6].However, the most alarming 
finding was their relation to an increased late thrombosis rate[7-10].  
Formation of atheromatic plagues may occur earlier, and more frequently, 
with drug-eluting compared to bare-metal stents, [11] resulting in high rates of 
early and late stent thrombosis after discontinuation of dual antiplatelet 
therapy, thus leading to ongoing susceptibility for thrombosis after the first 
year. Moreover, inflammation of the arterial wall, poor endothelisazation and 
delayed healing aggravated the risk for late thrombosis [12].  
Capitalizing on the significant superior effect of first generation DES on target 
vessel revascularisation (TVR) [13], a new (second generation) category of 
DES with innovative materials and antiproliferative agents were developed to 
cope with this issue. Second generation DES have been established as the 
cornerstone in PCI in patients presenting with coronary artery disease[14]. 
The majority of these agents were approved in non inferiority trials, compared 
to first generation DES or BMS[15]. 
Evidence based decision making in health requires the use of high quality 
Randomized Controlled Trials (RCT) that compare directly two (2) or more 
interventions and are undoubtly the cornerstone of informed decision making 
in health [16]. Nevertheless, the design of RCT is usually compared either to a 
placebo or an obsolete technology. Rarely does an RCT include all potential 
comparative products, primarily due to the high cost incurred, the regulatory 
impediments, as well as strategic decisions  
This creates a gap in the assessment process, which can be bridged with 
pioneering statistical methods, thus enabling the comparison of different 
treatments which form a connected treatment network but may not have been 
directly compared in trials [17-18]. In light of the above, we compare the 
safety and effectiveness profile between drug eluting stents and bare stents, 
using Mixed Treatment Comparisons (MTC, also known as network meta-
analysis or multiple treatment meta-analysis). MTC contribute further to the 
body of evidence by estimating the relative effects for treatments not directly 
compared, and by pooling both direct and indirect evidence, where available, 
to strengthen inferences. MTC are an extension of the standard (two-
treatment) meta-analysis to comparisons of more than two treatments forming 
a connected network of evidence (such as eg Fig 1), where all treatments and 
studies included are relevant to the decision[17-19].  
The current paper adheres to ISPOR-AMCP-NPC Good Practice Task Force 
Report for Indirect Treatment Comparison/Network Meta-Analysis Studies[20].  
We included 6 DES, 5 coated with mammalian Target of Rapamycin Inhibitors 
as coating agent – Zotarolimus, Everolimus, Sirolimus, Biolimus and 
zotarolimus resolute – and one antimitotic agent, paclitaxel.  This study 
advances further literature, since previous reports did not include 
comparisons between all commercially available stents [21-22], including 
BMS. 
2. Literature review  
We adopted the PRIMA [23] (Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses) statement for reporting systematic reviews and 
metanalysis in healthcare. We used the MESH terms:“drug eluting stent”, 
“bare metal Stent”, and also the INN of the drug used in the durable polymer 
stent (“sirolimus eluting stents”, “paclitaxel eluting stents”, “drug eluting stent” , 
“Endeavor zotarolimus stent”, “ biodegradable stent” 
“everolimus eluting stents”, “zotarolimus resolute etuling stent”, “biolimus 
eluting stent”  and “zotarolimus eluting stents”). The search lasted until the 
end of May, 2013. 
We searched Medline, the Cochrane database, Embase, TCTMD, 
ClinicalTrials.gov, Clinical Trial Results, CardioSource, abstracts and 
presentations from major cardiovascular meetings. We also searched for 
further articles cited by selected papers. Further, important conferences and 
relevant proceedings and abstracts, such as the American Heart Association, 
American College of Cardiology, Transcatheter Cardiovascular Therapeutics, 
Society of Cardiovascular Angiography and 
Intervention,  European Society of Cardiology, and Euro-PCR, were also 
searched. 
Lastly, we contacted authors, in cases of unclear data or in cases where 
clarification on study design was required.  
 
2.1. Selection of data 
 
Two (2) researchers (P.P and M.T.) independently critically assessed selected 
papers and there was a crossover of assessment: Any disagreements were 
resolved by consensus. Authors and manufacturers were contacted in case of 
discrepancy. 64 trials were included for short term studies and 42 for long 
term studies (table 1).  
Table 1.  
We used GRADE [24] criteria for assessment of evidence and also the 
Cochrane collaboration bias [25] tool. We defined several criteria for trial 
inclusion criteria as following: 
·  Randomised Controlled Trials (RCT).  
· Size of study ( ≥ 100 patients)  
· Duration more than 6 months. 
· Definition of reported endpoints  (TVR, THROMBOSIS, MI and 
Cardiac death ) 
 
2.2. Data extraction 
 
Due to several concerns regarding the short and long term safety of stents, 
along with a clear division of short and long term effects of stents, we created 
2 sub-analysis: Long-term (more than a year) and short term (less than a 
year- including studies that lasted 1 year). Endpoints were divided into 
efficacy and safety outcomes. The efficacy outcome was target-vessel 
revascularization (TVR) and the safety outcomes were cardiac death, 
myocardial infarction (MI),which includes fatal and non-fatal non-Q-wave or Q-
wave myocardial infarction, and stent thrombosis. Stent thrombosis was 
evaluated according to the Academic Research Consortium (ARC) criteria 
[26] and we included definite, possible, and probable and secondary 
thrombosis as well (i.e. after a repeated TVR). 
 
3. Statistical Methods 
We used mixed treatment comparison  (MTC) methods to create a 
comparative efficacy network of treatments which are relevant for medical 
decisions. This approach has two major advantages: 
 
· It allows estimation of relative treatment effects among products not 
clinically tested against each other, without breaking randomisation.  
· Inclusion of direct and indirect comparisons can reduce uncertainly and 
is the most efficient use of all relevant evidence.   
 
A MTC meta-analysis was conducted to simultaneously compare the 7 stents. 
The model used assumes the number of events (Cardiac Death, Thrombosis, 
TVR or MI), out of the total number of patients in each arm of each included 
trial follows a binomial likelihood with a certain probability of event which is 
modelled on the logit scale.[19] 
Relative treatment effects are reported as posterior median odds ratios (OR) 
and 95% Credible Intervals (CrI). We also present the probability of each 
treatment being ranked as 1st, 2nd, 3rd, etc. most effective for each outcome.  
The models were implemented using the freely available software Winbugs, 
version 1.4.3 [27] with code modified from Dias et al [28]. 
Both fixed and random effect models (where sufficient data was available) 
accounting for the correlations induced between trial-specific effects in multi-
arm trials were considered on the basis of model fit. Studies with zero or 
100% events in all arms were excluded from the analysis, because these 
studies provide no evidence on relative effects. 
Goodness of fit was measured using the posterior mean of the residual 
deviance, the degree of between study heterogeneity, and the Deviance 
Information Criterion (DIC). In a well-fitting model the posterior mean residual 
deviance should be close to the number of data points.[19,29] Heterogeneity 
was reported as the posterior median between trial standard deviation with its 
95% Credible Interval. Differences of ≥5 points for residual deviance and DIC 
were considered meaningful. Model fit was further assessed by inspecting 
individual data points’ contributions to the residual deviance[19]. 
For the selected model (fixed or random effects), inconsistency was assessed 
using the node-split method [30] implemented in R [31] through the gemtc 
package[32]. Comparisons of the direct and indirect evidence were made, and 
the probability of a difference quantified through a Bayesian p-value. The P-
values need to be interpreted with caution given the multiple direct vs indirect 
comparisons being carried out, and the direction and strength of direct and 
indirect evidence as well as model fit and between-study heterogeneity were 
also examined to determine whether there was evidence of inconsistency [30] 
 
3.1. Priors  
We used vague normal priors with mean zero and variance 10,000 for all trial 
baselines and relative effect parameters. In random effects models, the 
between-study heterogeneity was given a minimally informative prior, Uniform 
between zero and five. 
Model convergence was assessed through visual inspection of trace plots and 
through Brooks-Gelman-Rubin plots.  Convergence was achieved after 
40,000 burn-in iterations and we conducted at least a further 80,000 iterations 
(on three chains) to ensure stability and accuracy of results.  
4. Results  
In total the MTC analyses included 106 trials: 42 reporting long term 
outcomes with 48375 enrolees and 64 reporting short term outcomes with 
56709 enrolees. Treatment networks for each outcome are presented in 
Figure 1 where the width of the edges is proportional to the number of studies 
making that comparison and the size of the bubbles is proportional to the 
number of patients randomised to that treatment. 
FIGURE 1  
4.1. Model choice 
The Random Effects (RE) model was preferred for short term TVR, and the 
Fixed Effects (FE) model was preferred for thrombosis, MI and cardiac death 
for short term outcomes. In the long term assessment, the FE model was 
preferred for cardiac death and TVR, and the RE was chosen for MI and 
thrombosis. 
 
4.2.    Target Vessel Revascularisation   
All DES included in our analysis reduced TVR compared to BMS,  and all 
have demonstrated effectiveness both in long and short term with 95% 
credible intervals that exclude “no effect”.  
Long term: In the long term biolimus carries the highest probability (60%) of 
being the best agent, everolimus carries a 28.5% and Zotarolimus a 10% 
(table 2). Odds ratio between everolimus and biolimus is 1.08 (95%Credible 
Interval, CrI: 0.72-1.56)(table3).  
Short Term : Regarding short term TVR effectiveness, everolimus is the 3rd 
most potent agent, resolute zotarolimus carries a 70% probability of being the 
most effective, and biolimus 10% (table 4). The odds ratio of resolute 
zotarolimus compared to biolimus is 0.79 (CI:0.39-1.42) and of everolimus 
compared to resolute is 0.83 (0.46-1.35) (table 5). 
4.3. Thrombosis  
Long term: In the long term, results suggest that everolimus may be superior 
to BMS (table 3). Everolimus appears to be the safest stent, although with 
only a 27% probability of being the best, while resolute zotarolimus and 
biolimus demonstrate comparative probability of being the safest stent (25% 
and 24.5%, respectively) (table 2). 
Short Term : In the short term everolimus is superior to BMS, paclitaxel and 
sirolimus (table 5). Everolimus carries a dominating probability of being the 
most potent in reducing the probability of thrombosis (81%) whilst resolute is 
the second with a much smaller probability (12%)( table 4). 
4.4. Cardiac Death 
For cardiac death, another safety endpoint, there were no differences among 
agents in the short and in the long term (tables 3,5). 
Long term: Zotarolimus resolute appears to be the more potent, with a 47% 
probability of being the best in the long term(table 2) whilst Biolimus has 
18.7% probability of being the best stent.  
Short Term : Zotarolimus resolute also carries the highest probability (66 %) 
of being the best in the short term (table 4).  
 
TABLE 2 
TABLE 3 
TABLE 4  
TABLE 5  
 
 
4.5. Myocardial Infarction  
MI which includes fatal and non-fatal non-Q-wave or Q-wave myocardial 
infarction.  
Short Term: 
Everolimus, zotarolimus, resolute and sirolimus demonstrate short term 
statistically significantly potency compared to BMS (odds ratio BMS-Sirolimus 
0.74 CI: 0.6-0.90, BMS –everolimus 0.62  CI: 0.48-0.79, BMS: zotarolimus 
0.75 CI: 0.54-0.96, BMS-resolute 0.63 CI:0.45-0.85), while biolimus 
demonstrated a trend to statistically significant CI: 0.58-1.04. (table 5). 
Zotarolimus resolute demonstrated the highest probability of being the most 
potent (46%) while everolimus ranks second (39%) (table 4). Although 
superiority remains in the long term as well, results are not statistically 
significant except the borderline superiority of zotarolimus to paclitaxel (odds 
ratio CI:0.55-0.99)(table 4). Nevertheless, biolimus has a 45 % of being the 
best, with zotarolimus second 22% and resolute third with 13 % (table 
2)(Figure 2).  
FIGURE 2 
4.6. Inconsistency Checks  
Results of inconsistency checks are presented in Appendix 1. 
For TVR short term there was some evidence of disagreement between direct 
and indirect evidence in the comparison of everolimus with resolute 
zotarolimus. The P-value for inconsistency was 0.03, with direct evidence 
suggesting no effect whilst indirect evidence favoured zotarolimus resolute 
(Appendix 1).  
For MI short term there was some evidence of disagreement between direct 
and indirect evidence  for the comparison of biolimus with sirolimus, with 
direct evidence favouring sirolimus whilst indirect evidence showed no effect 
(P-value=0.02). No meaningful disagreement was identified for thrombosis or 
cardiac death in the short term analyses. 
For the long term inconsistency check, no meaningful disagreement was 
identified for the TVR or cardiac death. For MI we identified possible 
disagreement between direct and indirect evidence for comparisons of 
treatments sirolimus with biolimus and everolimus with biolimus. These two 
contrasts are both involved in the loop (sirolimus, everolimus, biolimus) and P-
value for agreement of direct and indirect evidence is 0.03 in both cases – 
indicating some inconsistency. For thrombosis there was some evidence of 
inconsistency in the comparison of Paclitaxel with everolimus with direct 
evidence suggesting a large effect favouring everolimus. 
5. Discussion 
85% of all inserted stents in Cyprus are DES, an approach similar to other 
countries[33]. Therefore, assessing safety and effectiveness of stents, apart 
from a health issue, will have a significant impact on relevant budgets [34]. 
In recently published meta-analyses of randomized controlled trials (RCTs) 
comparing BMS to DES, DES reduce restenoses and the need for 
revascularization procedures, but not overall mortality or the incidence of 
myocardial infarction [21-22]. In our MTC, we examined the safety and the 
efficacy of BMS, first and second generation DES, including biodegrabale and 
durable polymer stent.  
We can conclude that there is a notable variability among safety and 
effectiveness of DES. Even among second generation DES, there does not 
appear to be a class effect. Our analyses suggest that Everolimus is the 
safest, which is in line with other findings [21-22].  
The Thrombosis mechanism associated with DES is a complex process and 
the Polymer coating of DES may aggravate thrombogenivity compared to 
BMS [35]. Thrombosis, as a significant safety endpoint, has been amidst  a 
longstanding area of controversy.  
Everolimus demonstrated superior safety, which can also be attributed to its 
biodegradable polymer.  In our analysis, thrombosis rates tend to favour 
second generation stents, as compared to both first generation and BMS. 
Thrombosis still remains a multifactorial issue with many variables, including 
the kinetics of drug release, the type of polymer, and strut thickness, have an 
impact on thrombosis rates. The FDA responded to these concerns by 
amending the guidelines related to antiplatelet duration in patients after stent 
placement [36]. Still, the optimal use of antiplatelet therapy is not defined, and 
thrombosis with DES, as well BMS, remain an adverse event that may occur. 
In the era of BMS stents, thrombosis after the first month was very rare [37]. 
Several authors highlight the long term risk for thrombosis with DES[38]. The 
addition of antiproliferative agent interacts between the coagulation process 
and the stent[39]. As a result, rapamycin inhibition of the mammalian target of 
rapamycin increases both the thrombin- and tumor necrosis factor-α–induced 
endothelial tissue factor expression [40]. Consequently, many authors [41-42] 
underline the need for longer use of antiplatelet therapy, which increases both 
cost and risk for adverse events.  
Biolimus, proved to be the most potent, with regards to TVR reduction in the 
long term, however, other meta-analyses did not include it[20-21]. All DES 
were superior to BMS in reducing TVR, but there is variability in the size of the 
effect, Zotarolimus is the only second generation DES that did not 
demonstrate superiority compared to BMS and 1st generation stents. 
Nevertheless, since resolute zotarolimus was superior to BMS, this difference 
may be due to the release curve of the resolute zotarolimus, which further 
substantiates the hypothesis that other variables , beyond eluting stent, may 
influence the outcome. 
From a health policy perspective, the hardest challenge is the combination 
and ranking of all four endpoints, especially TVR risk against thrombosis.  
TVR has a prevalence of 15% of patients involved in the analysis. In the 
majority of cases, it is angiographically driven by strict study protocol, without 
clinical symptoms, and consequently, associated with a low risk of death. On 
the other hand, even though thrombosis is rare, it is related to a 90% risk of 
death or MI [43]. Stone et al reported incidence rates for target lesion 
revascularization of 7.8% with SES vs 23.6% with BMS (p < 0.001) and 10.1% 
with PES vs 20.0% with BMS (p < 0.001) after a four year study[44]. The 
corresponding rates for thrombosis were only 1.2% with SES versus 0.6 with 
BMS (p = 0.20) and 1.3% with PES versus 0.9% with BMS (p = 0.30)[44].   
Other authors did not find a statistically significant difference in primary safety 
endpoints (MI and death) between DES and BMS, which was another finding 
of our study. Nevertheless, DES were proved to be superior to BMS, with 
biolimus and resolute being the most potent in reducing  MI and cardiac death 
rates.  
Overall, our findings indicate that DES and BMS demonstrated similar rates of 
cardiac death and MI. DES are also statistically superior in TVR reduction 
compared to BMS, while  biolimus and everolimus are superior compared to 
other stents. Moreover, DES are not associated with an increased rate of 
thrombosis. DAPT (antiplatelet therapeutic regime of aspirin plus platelet P2Y12 
receptor blocker) offers significant benefit in preventing stent thrombosis.  
Without  DAPT, the period of high risk for stent thrombosis is longer with DES 
than BMS, due to a delay in neointimal coverage. Therefore, bare-metal 
stents are often used in patients with a history of bleeding, needing early non-
cardiac surgery, requiring anticoagulation in addition to dual antiplatelet 
therapy, or those who are non-compliant with their treatments.  
We also point out that adoption of DES has exceeded the clinical evidence, 
mainly due to their high and early uptake and the off-label use. Relief of 
symptoms and a desire to avoid extensive procedures may be the most 
important factors to patients. Moreover, the concurrent angiography and 
placement of stents seems rational for many patients. There is a perception 
among patients that PCI prevents heart attacks[45], while several authors 
underline that stenting was the only therapeutic option offered to patients  
Stent implantation has become the cornerstone therapeutic approach in 
coronary artery disease[46] while CABG rates are declining worldwide. 
Although the scope of this report is to compare DES with BMS, we deem fit to 
comment on CABG. CABG, which denotes the surgically bypass of blocked 
arteries by using grafts from internal mammary arteries or saphenous arteries, 
is the benchmark procedure in cases such as failed PCI and significant left 
main coronary disease. CABG has demonstrated increased life expectancy in 
multi vessel disease and diffused diseases; however, the benefit is long term 
(after 5 years)[47] and comes along with certain risks, such as increased 
recovery period and susceptibility to infections. Utilisation of stents, is steadily 
increasing in stable patients with Coronary disease [48]. Along with stent 
evolution, medical therapy has also improved dramatically over this period. 
The Clinical Outcomes Utilizing Revascularization and Aggressive Drug 
Evaluation (COURAGE) trial, compared an initial strategy of aggressive 
medical therapy versus PCI with BMS in patients with stable CAD and found 
no statistically significant survival difference, although greater symptom relief 
was associated with PCI[49] .Thus, the decision to perform a PCI in patients 
with stable angina is based on its effectiveness in relieving symptoms, 
preventing recurrent angina, and reducing repeat procedure.  
Therefore, stents - both DES and BMS- must also be assessed in the broader 
context with other available interventions, both pharmaceutical and medical. 
An implication of using MTCs is that, unlike the process for regulatory 
approval, the results of one company´s trial may influence the estimated 
relative effectiveness of another company´s product, even in cases where the 
other product is not used as a trial comparator. 
6. Conclusion  
Taking everything into account, the MTC method is a particularly important 
methodological development in technology appraisal because it potentially 
offers a potent answer to synthesis, in contexts where individual or pair-wise 
meta-analyses of trials do not provide coherent estimates of all the 
effectiveness parameters, as is often required to inform associated economic 
decision models. MTC methods are perhaps the most important development 
in evidence synthesis in recent years and their potential for use in technology 
assessment is considerable. 
This MTC provides one of the most comprehensive comparisons in DES and 
BMS, including 56709 patients in the short term analysis, plus 48375 patients 
in the long term.  
Based on the rankings of each treatment, a distinct difference between 2nd 
and 1st generation stents was identified . We can conclude that everolimus, 
resolute and biolimus carry the highest probabilities of being superior for all 
endpoints. 
 Table 6 
Study Year  Comparative 
Arms  
Sex  Age  
BASKET [50]  2005 SES (n=264), 
PES 
 (n=281), 
 BMS (n=281) 
Male 
(79%)  
Male (79%) 
 
 
Age (years) 64±11 Age 
(years) 64±12 
CATOS[51] 2012 ZES (n=80 ) 
SES  (n=80), 
Male (65%) 
Male (76%) 
Age (years) 62.7±12.3 
Age (years) 63.0±11.7 
C-SIRIUS[52]  
2004 
SES(n = 50), 
BMS(n =50) 
Male (70 %)  
Male (68%) 
Age (years) 60.3 ±10.6, 
 Age (years) 60.7± 9.1, 
CHEVALIER [53] 2007 BES 
(n=85),PES 
(n=35) 
 Male (69 %) 
Male (66%) 
Age (years) 65±11, Age 
(years) 63±11 
COMFORTABLE AMI[54] 2012 BES (n = 575) 
BMS(n = 582), 
 Male  
(80.5%), 
Male  
(78.2%) 
 
Age ,(years) 60.7±  
11.6, Age, (years), 60.4 
± 11.9 
COMPARE [55] 2010  EES(n=897), 
PES (n=903)  
Male (69%),  
Male 
 (72%) 
Age (years)62.9 ± 
15.7,Age (years) 
63.6±17.2  
COMPARE II[56] 2013 BES(n=1795) 
EES(n=912) 
Male 
(74?4%), 
Male(74.3%) 
Age (years) 63± 11.1, 
Age (years) 62.7± 11.0 
DEBATER[57] 2 0 1 
2 
SES (n =424) 
BMS (n = 446 
Abciximab(n = 
439) , No 
Abciximab (n 
= 434) 
Male  (78%), 
Male (75%), 
Male  (76%) 
Male (78%) 
Age(years) 60±11 Age 
(years) 61±11 Age 
(years) 60±10 , Age, 
(years)60±12 
DESSERT[58]  2008 SES(n = 75) 
 BMS (n = 75) 
Male(63%), 
Malen(49%) 
Age (years) 71 ±9 Age 
(years) 69±9, 
DIABEDES[59] 2007 SES(n = 76) 
PES(n =77) 
Male  (84%) 
 Male (74%), 
Age (years) 66 ±8, Age 
(years) 65 ±10 
DIABETES[60] 2005 SES (n = 80) 
 BMS (n = 80) 
Male (70%) 
Male  (81%) 
Age (years)  
65.9±9 6 
Age (years) 
7.2±10 
DIAS DE LA LIERA[61] 2007 BMS 
(n = 54),  
SES 
(n = 60) 
Male  
(78.3%) , 
Male (80.0) 
Age, (years)  65 ±13 64  
DIBRA[62] 2005 BMS(N=125), 
SES(N=125), 
Male (64%), 
Male (68%) 
Age (years) 68.3±9.6 
Age (years) 67.7±10.2 
 
E-SIRIUS[63] 2003 SES (n=175), 
BMS (n=177), 
Men (70%), 
Men 126 
Age (years) 62·0 ±11·4,  
age (years)62·6±10·3, 
(71%), 
ENDEAVOR II[64] 2006 EES(n=598), 
BMS (n=599) 
Male (77%), 
Male  (75%) 
Age(years)61.6±10.5, 
Age (years) ,61.9±10.5 
ENDEAVOR III[65] 2006 ZES(n=323), 
SES (n=113)  
 
Male  
(65.3 %)  
Male 
 (81.4 %)  
 
Age (years) 61.42 
±10.58, 
Age (years) 61.73 
±11.59  
 
ENDEAVOR IV [66] 2010 ZES  (n =773) 
 PES (n =775), 
Men 
(66.9%) 
Men 
(68.5%)  
Age, (years) 63.5± 11.1  
Age( years )63.6 ± 11.0 
ESSENCE DIABETES[67] 2013 EES(n=149) 
SES(n=151) 
Men 
(52.3%) 
,Men 
(65.6%)  
Age (years) 63.2±8.3, 
Age (years )63.5±8.1 
EXCELLENT[68] 2011 EES (n = 
1,079), SES (n 
= 364) 
Male  
(65.2%) 
Male  
(62.6%) 
 
Age (years) 62.5 ±10.1 
Age (years) 63.4  ±9.9 
 
Erglis[69]
 
 2007 BMS (n =50) ), 
PES (n = 53)  
 
Male (82%) 
Male (85%) 
Age  (years) 62.56  
±11.45,  Age(years) 
61.08± 10.28,   
HORIZON AMI STONE 
[70] 
2009 PES(N = 
2257)  
 BMS (N = 
749)  
 
Male . 
(77.0%), 
Male 
(76.0%) 
 
Age (years) 59.9  
Age (years)  59.3 
 
LEE [71] 2008 SES(n = 200), 
PES 
(n =200) 
 
 
Men 
(61.0%) 
Men(55.0%) 
Age (years) 61.1± 8.9 , 
Age (years), 60.7  ±8.8 
EUROSTAR[72] 2011 PES (n=152) 
BMS (n=151) 
Male 
(74.3%),  
Male  
(68.9%) 
Age (years) 64.9±9.2, 
Age (years) 66.2±9.4 
 
EXAMINATION [73] 2012 EES (n=751 
BMS (n=747)  
 
Male (82%) 
Male  (84%),  
 
Age (years), 
60±8  
Age (years),   
61±6  
 
ISAR LEFT MAIN[74] 2009 PES (n = 302)  
SES (n = 305)  
 
Μale (23%), 
Male (38%) 
Age, (years) 68.8± 10.1 
Age, (years) 69.3  ± 
9.34,  
 
JUWANA [75] 2009 SES(n = 196)  
PES(n=201)  
 
Men (69%),  
Men(74%) 
 
Age (years)  
61± 11,  
 
KIM [76] 2008 SES  
(n = 85),  
PES (n = 84) 
Male  
(71.8%), 
Male  
(76.2%) 
Age (years) 62.9 ± 8.0 , 
Age (years) 61.5 ± 8.9 
LEADERS[77]  2008 BES (n=857)  
SES(n=850)  
 
Men 
 (75%),  
Men  (74%) 
 
Age (years) 64.6 ±10.8,  
Age (years) 64.5 ±10.7 
 
LONG DES II[78] 2006 SES (n=250)  
PES(n=250)  
 
Male  
(67.2%) 
Male 
(61.2%) 
 
Age (years)61.4 
Age (years) 60.7 
 
LONG DES III[79] 2 0 1 
1 
EES (n = 224)  
SES(n =226)  
 
Male 
(73.7%),  
Male(65.9%) 
 
Age, (years) 62.9 
Age, (years) 63.0 
 
LONG DES IV[80] 2012 RESOLUTE-
ZES (n= 250) 
SES (n=250 )  
 
Male , 
(73.6%)  
Male, 
(72.4%) 
 
Age (years)62.8±9.7, 
Age,(years)62.7±9.8,  
 
LIPSIA[81] 2 0 1 
1 
SES(n= 120)  
PES(n= 
116)  
 
Male (69%),  
Male (68%) 
 
Age(years) ,67.0±9.5 
Age (years), 67.3±9.1,  
 
MISSION [82] 2008 SES (n = 158)  
BMS (n = 152) 
 
Male (69%),  
Male (68%) 
 
Age (years) 59.2   
Age (years) 59.1  
 
MULTISTRATEGY[83] 2008 Abciximab 
Plus BMS(n = 
186)  
Abciximab 
Plus (n = 186)  
Tirofiban Plus 
BMS (n = 186)  
Tirofiban Plus 
SES(n = 186)  
 
Male 
(73.1%),  
Male  
(72.6%),  
Male 
(79.5%),  
Male 
(78.5%) 
 
Age, (years) 63.9 
±11.7,  
Age, (years) 62.7± 11.2  
Age, (years) ,65.4 
±12.1 
Age,(years),63.4±12,  
 
Natsuaki [84] 2013 BES (n=1617) 
EES (n=1618) 
Male  (77%), 
Male (77%) 
Age (years) 69.1±9.8,  
Age  (years) 69.3±9.8,  
PACHE MEHILI [85] 2005  PES (n= 250) 
BMS(n = 250) 
Men (78%) 
Men (78%) 
Age (years ) , 
67.4±16.4 
Age, (years) 66.7 ± 
14.8 
PAINT[86] 2009 PES (n =111)  
BMS(n = 57)  
SES(n = 106)  
 
Men (61.3 
%) 
Men 
(67.0%) 
Men 
(66.7%),  
 
Age, (years) 60.1  
 ± 10.2 
Age, (years)59.7 ±10.6,  
Age, (years)58.5 ± 9.6 
 
PROSIT[87] 2008 SES (n=  154) 
PES (n = 154) 
Male 
(76.0%) 
Male(76.6%) 
Age (years) 60 .6 ±11 
Age(years),60 .6 ±12 
NOBORI[88] 2011 BES(n  
=194)  
SES(n =132)  
 
Male 
(71.6%),  
Male  
(72.0%) 
Age (years) 67.1 ± 10.3 
Age (years)67.7 ± 9.3,  
 
 
PAN[89] 2012 SES(n = 145)  
EES(n = 148) 
 
Male (79%) 
Male  
 (82%),  
 
Age (years) 63  ±  10 
Age (years) 63 ±  11 
 
RAVEL[90] 2002 SES 
(n=120)  
BMS (n=118)  
 
Male  (70%),  
Male (81%) 
 
Age (years) 61.8±10.7, 
Age (years) 59.7±10.1,  
 
REALITY[91] 2006 SES(n = 684)  
PES(n = 669)  
 
Men 
(72.0%) 
, Men  
(74.1%) 
 
Age 
(years) 62.6 ±10.5,  
Age 
(years) 62.6 ± 
10.0,  
 
REMEDEE[92] 2 0 1 
3 
SES(n = 124)  
PES(n=59)  
 
Men 
(71.8%), 
Men(71.2%) 
 
Age (years) 64.20 
±9.48 
Age (years) 64.05 ± 
10.49 
 
RESET[93] 
 
2013 SES (n=1600) 
EES (n=1597 ) 
 
Male 
(12.17%), 
Men(76%) 
Age(years) 68.9±9.7, 
Age (years) 69.3±9.6,  
 
RESOLUTE[94] 2 0 1 
3 
RESOLUTE 
ZES(n=198)  
PES(n = 202)  
 
Male  
(77.8%),  
Male  
(80.7% ) 
 
Age, (years) 59.7±9.9,  
Age, (years)59.6±10.6,  
 
SEPARHAM [95] 2011 BES (n=100) 
EES (n=100) 
 
Male (66%) 
Male (64%) 
Age, (yrs)60.60±9.1, 
Age, (yrs) 62.38±10.2 
SESAMI [96] 2007 SES (n = 160)  
BMS (n = 160)  
 
Male  (80%),  
Male  (80%),  
 
Age (years) 63±20, 
Age (years) 62 ±16 
 
 
SEZE[97] 2012 ZES  
(n=60)  
SES (n=61)  
 
Male 
(81.6%) 
Male ( 
80.3%)  
 
 Age (years) 59.8±13.3  
Age (years)  
62.0±11.5  
 
SERRYUS[98] 2010 ZES (N = 
1152)    
EES (N = 
1140)   
 
Male 
(76.7%),  
Male 
(77.2%),  
 
 Age ( years)    
64.2±10.8 
Age( years)  64.4±10.9 
 
SORT OUT  IV[99] 2012 SESn=1384 
EES n=1390 
Men 
(75.5%), 
Men  
(72.4%). 
 
Age (years) 64.1± 10.8,  
Age(years)  63.5 ±13.2,  
 
SORT OUT  V [100] 2013 BES(n=1229)  
SES(n=1239)  
 
Men 
(74·6%), 
Men 
(75·1%) 
 
Age  
(years) 65·0 ±10·6,  
Age (years) 65·2 ±10·3,  
 
SPIRIT III STONE [101] 2008 EES  (n=669) 
PES (n= 
332) 
Men  
 (70.1%),  
Men 
(10.2%) 
 
Age,  (years) 63.2± 
10.5,  
Age (years) 62.8 ±10.2,  
 
SPIRIT IV [102]  2013 EES 
(n = 2458) 
PES 
(n = 1229 ) 
Male  
(67.7%),  
Male 
(67.8%) 
 
Age (years) 63.3±10.5 
Age  (years) 63.3±10.2 
 
SPIRIT V [103]  EES(n = 218)  
PES(n = 106)  
 
Male (70 %) 
Male (67% ) 
Age (years) 65 ± 10 
Age (years) 66 ±  
9,  
 
STEALTH[104] 
 
2005 BES (n=80)  
BMS (n=40) 
Male  (48%),  
Male  (33%) 
 
Age 
(years) , 62.2 ± 10.1 
Age (years) , 61.1 ± 
9.4,  
 
ZEST AMI [105] 2009 ZES n=( 108) 
SES 
(n = 110) 
PES 
(n =110) 
Male 
(77.8%) 
Male  
(86.4%) 
Male  
(82.7%) 
Age, (years) 61.9  ± 
11.0, Age (years),  57.8 
± 11.3 Age (years) , 
59.3  ±  11.2 
TAXI [106] 2005 PES (n = 100)  
SES(n = 102)  
 
 
Male(83%) 
Male 
(79/%),  
 
 Age (years) 63 ± 10 
 Age (years) 65± 10 
 
TAXUS VI[107] 2005 PES 
(n = 577)  
, BMS (n = 
579)  
 
Male 
(70.2%),  
Male 
(68.7%) 
 
Αge  (years) 62.9 ± 
11.2,  
Age,   
(years) 62.8 ±10.8,  
 
TAXUS[108] 2005 PES (n=219)  
BMS(n=227),  
 
Male,   
(76.3%)  
Male,  
(76.2%)  
 
Age (years )61.8±9.7,  
Age (years) 63.4±9.9,  
 
TYPHHON [109] 2006 SES(N = 355)  
BMS(N = 357)  
 
Male 
(78.6%),  
Male 
(78.2%),  
 
Age  (years) 58.0,  
Age (years)  60.5,  
 
TWENTE[110] 2012 
 
 RESOLUTE 
ZES  
(n =697), EES  
(n=694) 
Men 
(72.5%), 
Men 
(72.6%) 
Age (years) 64.2 ± 10.8 
, Age (years) 63.9±  
10.9, Age  (years) 64.5 
±  10.7  
XAMI[111] 2012, EES (n=404)  
SES (n = 221)  
 
Male  
(73.0%)  
Male 
(75.1%)  
Age (years) 61.2 ± 
11.3,  
Age (years) 62.0± 11.4 
 
 
ZEST[112] 2010 ZES (n=883) 
SES (n =878) 
PES (n=884)  
 
Male 
(66.4%), 
Male  
(67.3%), 
Male  
(65.8%) 
 
Age, (years) 61.7±  9.3,  
Age, (years) 61.9  ±9.6 
Age, (years) 62.0 ± 9.6,  
 
ZOMAXX[113] 2011 ZES(n=557) 
PES(n=542),  
 
Male ( 69%),  
Male ( 69%) 
 
Age (years) 63±10 
Age (years) 63±11 
 
 
     
BASKET  PROVE KAISER 
[114] 
2013 EES (n=774)  
SES (n=775) 
BMS (n=774)  
Male(76%)Mal
e(74%) 
Male(77%) 
Αge(years) 
66±11 
 Age 
(years)66±1
1  
Age (years) 
67±11 
Byrne[115] 2010 SES (n = 335), 
ZES (n = 339). 
Male (77.3%)  
Male (75.5%) 
Age (years ) 
66.6±11.1 
Age 
(years)67.2 
±10.9 
COMPARE[116] 2011  
EES 
(n = 897) 
PES 
(n = 903) 
 
Male(69%) 
Male (72%) 
 
Age 
(years)62.9 
± 15.7,Age 
(years) 
63.6±17.2 
DES DIABETES[117] 2011 SRL( n=200) 
PES(n =200) 
Male (61%) 
Male (55%) 
Age (years) 
61.1±8.9 
Age 
(years)60.7±
8.8, 
ENDEAVOR II FIVE 
YEARS[118] 
2010 ZES(n= 598),  
BMS(n =599) 
Male(77.2%)  
Male (75.4%) 
Age, (years)  
61.6±10.5  
Age, (years) 
61.9±10.5 
ENDEAVOR III 5 YEARS 
[119] 
2011 ZES (n = 323), 
SES (n=113) 
Male(65.3% ) 
Male(81.4%) 
Age (years), 
61.42±10.58 
Age (years), 
61.73±11.59
,  
 
ENDEAVOR IV[120] 2013 ZES(n= 773)  
PES(n= 775)   
Male(66.9%) 
Male(68.5%) 
Age, (years 
)63.5±11.1  
Age, (years 
)63.6±11.0 
GISSOC [121] 2010  BMS(n = 78) 
SES(n = 74) 
Male  (87.1%), 
Male (78.3%) 
 
Age (years) 
63.9±9.8, 
Age 
(years)63.9±
9.6, 
HONG[122] 2010 SES  (n =85) 
PES  (n =84) 
Male (71.8%) 
Male (76.2%) 
Age (years) 
65.9±  8.0, 
,Age (years) 
64.5±  8.9,  
 
HORIZON AMI[123] 2011 Heparin plus a 
GPI(n=1802), 
Bivalirudin 
monotherapy(n
=1800) 
PES(n=2257), 
BMS(n=749)  
 
Male (76%) 
Male (77%), 
Male (76%) 
Age (years) 
60.7± 17.2 
Age (years) 
59.8±17.6   
Age (years) 
59.9±17, 
Age (years) 
59.3±17.4  
ISAR LEFT MAIN [124] 2009  
PES (n = 302) 
SES (n = 305) 
Male(75%) 
Male(80%) 
 
Age, (years)  
68.8 ± 10.1 
Age (years) 
69.3 ±9.34  
 
Klaus [125] 2011  BES (n = 
857),  
SES (n = 850),  
 
Male (75%) 
Male (74.6%) 
Age, (years) 
64.6±10.8 
Age, (years) 
64.5±10.7 
KOMER[126] 2011 ZES (n=205) 
SES (n=204) 
PES (n=202) 
Male(76%) 
Male(81%) 
Male(79%) 
Age, (years) 
60±13  Age 
(years), 
59±12,  
Age(years) 
,60±13,  
Leaders [127] 2011 BES(n= 857) , 
SES(n= 850)  
Men 
 (75%),  
Men  (74%) 
 
Age (years) 
64.6 ±10.8,  
Age (years) 
64.5 ±10.7 
 
LATE [128] 2011 SES (n=503), 
PES(n= 509)  
Male(76%), 
Male(78%) 
Age (years) 
62±11   
Age (years) 
62±12 
MISSION [129] 2012 SES (n=158) 
BMS (n=152 
Men (74.7%) 
Male(80.9%) 
 
Age (yrs)  
59.2±11.2  
Age (yrs)  
59.1±11.6 
 
NAPLES DIABETES [130] 2011 SES (n=76) 
PES  (n=75), 
EES 
 (n=75) 
Male (57%),  
Male (59%) ,  
Male (56%) 
 
Age, (years) 
64±8, Age, 
(years) 
64±10 Age, 
(years) 
65±8, 
MULTISTRATEGY [131] 2013 SRL(n=  370) 
BMS(n=372) 
Male (73.1%) 
Male (72.6%)  
Age 
(years)63.9 
±11.7 
Age (years) 
62.7 ± 11.2 
Age (years)  
65.4 ±12.1 
  Age 
(years) 63.4 
±12 
PAINT [132] 2012 PES (n=111) 
SES (n=106)  
BMS(n=57) 
 
Male(61.3 %) 
Male(67.0%) 
Male(66.7%) 
Age, (years) 
60.1±10.2 
Age (years) 
59.7±10.6 
Age (years) 
58.5±9.6 
PASEO [133] 2009 BMS (n = 90 ) 
PES (n =90) 
Male(71.1% ) 
Male(68.9%) 
Age, (years) 
62± 17,  
Age (years) 
63± 15 
 
PASSION [134] 2011 PES(n=  310) 
BMS 
(n = 309) 
Male(73.9%) 
Male(78%) 
Age, (years) 
61±12, 
 Age, 
(years) 
61±13 
 
PRISON[135] 2012 BMS(n=100) 
SES (n=100) 
 
Male (76%)  
Male(83%) 
Age (years) 
59.3±10.2 
Age (years) 
59.6±10.6  
 
PROTECT [136] 2012 EES (n=4357) 
SES (n=4352) 
Male(77%) 
Male (76%) 
Age (years) 
62·3 ±10·6,  
Age (years) 
62·1± 10·7 
PROSIT  [137] 2011 SES (n = 154) 
PES (n = 154) 
Male(76%) 
Male(76.6%) 
Age (years), 
60 .6 ±11,  
Age (years), 
60. 6 ±12 
PURICEL [138] 2013 ERL(n= 200) 
BES(n= 200) 
Male(75.5%) 
Male( 73%) 
Age (years ) 
65.9±11.2  
 Age (years) 
64.9±10. 
 
RAVEL [139] 2007 SES(n= 120) 
BMS (n=118) 
Male(70%/ ) 
Male(81%) 
Age (years) 
61.8±10.7 
Age (years) 
59.7±10.1 
 
RESOLUTE[140] 2011 RESOLUTE -
ZES(N=1140) 
EES(N=1152) 
Male(76.7%)  
Male(77.2%) 
Age (years) 
64·4 ± 10·9, 
Age (years) 
64·2 ± 10·8 
 
 SCOPRIUS[141] 2012 SES (n = 95) 
BMS (n = 95) 
Male(66%) 
Male(62%)  
Age (years) 
66 ± 9,  
Age (years) 
66 ± 10 
 
SEASIDE [142] 2011 SES (n= 75)  
ERL (n= 75) 
Male(75%) 
Male(85%) 
Age, (years) 
64±10  
SESAMI[143] 2011 SES( n=155 ) 
BMS (n=155)  
Male(82%) 
Male(81%) 
Age, (years) 
63±15,  
Age (years) 
63± 19 
SIRTAX [144] 2008 SES(n= 503)  
PES (n = 509 ) 
Males (69.4%)  
Male(72.0%) 
Male (79.8%) 
 
Age (years) 
62 ± 10 
SORT OUT III 18 MONTHS 
[145] 
2010 ZES (n = 1,162) 
SES 
(n =1,170) 
 
Male(73% ) 
Male(74%)  
Age(years), 
64.3± 10.7 
Age (years), 
64.3± 10.8 
 
SORT OUT III[146] 2012  ZES (n = 1,162) 
 
SES 
(n = 1,170) 
 
Male(73% ) 
Male(74%)  
Age, (years) 
64.3± 10.7, 
Age (years) 
64.3±10.8 
 
SORT OUT IV [147] 2012 EES 
(n=1390), 
 
SES 
(n=1384), 
 
 
Male(75.9% ) 
Male(75.2% ) 
Age years , 
64.2 ±10.9, 
Age  years, 
64.0±10.8 
SPIRIT II 3 YEARS [148] 2009 EES 
(n = 223) 
PES 
(n = 77) 
 
Male(71%) 
Male(79%) 
Age (years) 
62±10, Age 
(years) 62±9  
 
 TAXI LATE [149] 2007  SES(n= 100) 
PES (n= 102) 
Male(77%), 
Male(83%) 
Age (years), 
65. 6±10, 
Age (years) 
,63. 6± 10 
TAXUS [150] 2011 BMS (n=1397) 
PES (n=1400) 
Age (81,7%) 
Age (71.5%) 
Age (years), 
62.2±10.7  
Age (years), 
62.8±11.0 
TAXUS IV[151] 2009  
BMS (n=643) 
PES (n = 651 
Male (72.2%) 
Male(71.7%) 
 
Age (years) 
62.1±11.0  
Age  (years) 
62.8±11.2 
TAXUS VI[152] 2009 BMS (n=233 ) 
PES(n =217) 
Male (70.2%),  
Male (68.7%) 
 
Αge  (years) 
62.9 ± 11.2,  
Age,   
(years) 62.8 
±10.8,  
 
TWENTE[153] 2013  Resolute- ZES 
(n= 697) 
EES(n= 694) 
 
Men  (72.5%) 
Men (72.6%) 
 
Age (years) 
63.9 ± 10.9,  
Age (years) 
64.5 ± 10.7 
 
Typhoon[154] 2011 SES (n=355) 
BMS (n=357) 
Male (77.7%) 
Male(78.6%) 
Age, (years) 
59.3±13.2 
Age, (years) 
59.2±11.7, 
ZOMAXX[155] 2013 ZES 
(n=199) 
PES 
(n=197) 
Male (75%) 
Male(77%) 
 
Age (years) 
63 ± 10  
Age (years) 
63 ± 11  
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Not enough data n=4 
No stent definition n=4 
 
 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 106 ) 
Table 1
TABLE    2.  LONG TERM PROBABILITY               
 
AGENT  PROBABILITY  
BEST % 
REDUCING 
CARDIAC 
DEATH  
FIXED 
EFFECT 
PROBABILITY  
BEST % 
REDUCING 
MI 
RANDOM 
EFFECT 
PROBABILITY  
BEST % 
REDUCING 
TVR  FIXED 
EFFECT 
PROBABILITY  
BEST % 
REDUCING 
THROMBOSIS 
RANDOM 
EFFECT 
     
BMS 3.6 2 0 6 
SIROLIMUS 8.7 12 0    0.5 
EVEROLIMUS 6.9 3    28.5 27.8 
PACLITAXEL 7.2 0 0 0.5 
ZOTAROLIMUS 7.4    22.4 0 15 
BIOLIMUS  18.7    45    60.8    25 
ZOTAROLIMUS RESOLUTE   47.37 13    10.5    24.5 
     
  
   
  
Table 2
Table 3. Odds ratio Long  Term   
  
 Comparator CARDIAC 
DEATH 
ODDs 
RATIO  
FE 
95% CI MI 
ODDS 
RATIO  
RE 
95% CI TVR ODDs 
RATIO FE 
97.5% CI THROMBOSIS 
ODDS RATIO 
RE 
97.5% CI 
BMS          
 SIROLIMUS 0.92 0.73-
1.13 
0.87 0.67-1.12 0.401* 0.35-0.45*
  
1.09 0.79-1.46 
 EVEROLIMUS 0.94 0.71-
1.22 
0.99 0.69-1.46 0.33* 0.28-0.39* 0.86 0.52-1.34 
 PACLITAXEL 0.95 0.78-
1.15 
1.20 0.94-1.53 0.61* 0.55-0.68* 1.17 0.84-1.58 
 ZOTAROLIMUS 1.01 0.73-
1.37 
0.87 0.61-1.22 0.59* 0.50-0.70* 0.94 0.60-1.44 
 BIOLIMUS 0.95 0.65-
1.35 
0.82 0.47-1.30 0.32* 0.25-0.40* 0.98 0.50-1.76 
 RESOLUTE   0.88 0.50-
1.42 
1.07 0.56-1.93 0.38* 0.28-0.50* 1.03 0.42-2.14 
SIROLIMUS          
 EVEROLIMUS 1.02 0.83-
1.25 
1.15 0.81-1.62 0.84* 0.74-0.95* 0.79 0.50-1.18 
 PACLITAXEL 1.04 0.85-
1.26 
1.39 1.08-1.76 1.54 1.36-1.74* 1.08 0.79-1.42 
 ZOTAROLIMUS 1.10 0.84-
1.42 
1.00 0.73-1.35 1.48  1.26-1.73* 0.86 0.58-1.26
  
 BIOLIMUS 1.04 0.76-
1.38 
0.94 0.57-1.40 0.80* 0.66-0.97* 0.89 0.49-1.51 
 RESOLUTE  0.95 0.57-
1.50 
1.23 0.66-2.18 0.94 0.71-1.23 0.95 0.40-1.92 
EVEROLIMUS          
 PACLITAXEL 1.02 0.79-
1.30 
1.24 0.84-1.69 1.84 1.56-2.15* 1.41 0.88-2.13 
 ZOTAROLIMUS 1.08 0.77-
1.48 
0.89 0.59-1.24 1.77 1.45-2.14* 1.13 0.70-1.77 
 BIOLIMUS 1.02 0.70-
1.42 
0.84 0.44-1.35 0.96 0.76-1.20 1.18 0.56-2.22 
 RESOLUTE  0.93 0.58-
1.40 
1.07 0.63-1.68 1.12 0.87-1.42 1.20 0.59-2.19 
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PACLITAXEL          
 ZOTAROLIMUS 1.06 0.77-
1.43 
0.72 0.52-0.99* 0.96 0.81-1.13 0.81 0.54-1.20 
 BIOLIMUS 1.00 0.69-
1.40 
0.68 0.39-1.07 0.52* 0.41-0.65* 0.84 0.43-1.51 
 RESOLUTE  0.92 0.53-
1.47 
0.89 0.47-1.58 0.61* 0.45-0.81* 0.89 0.37-1.82 
          
ZOTAROLIMUS          
 BIOLIMUS 0.95 0.62-
1.39 
0.96 0.52-1.54 0.54* 0.42-0.69* 1.072 0.51-1.96 
 RESOLUTE  0.88 0.48-
1.46 
1.24 0.65-2.22 0.64* 0.46-0.86* 1.124 0.45-2.29 
BIOLIMUS          
 RESOLUTE 0.94 0.51-
1.58 
1.37 0.64-2.80 1.18 0.83-1.63 1.147 0.39-2.6 
          
Median estimate of heterogeneity 
 ( 95% CrI) 
 NA  0.23 0.03-0.48 NA  0.27 0.03-0.53 
          
* evidence of a significant effect  
 
TABLE 4 SHORT TERM PROBABILITY  
 
              
AGENT  PROBABILITY  
BEST % 
REDUCING 
CARDIAC 
DEATH FIXED 
EFFECTS  
PROBABILITY  
BEST % 
REDUCING 
FIXED 
EFFECTS MI  
PROBABILITY  
BEST % 
REDUCING 
TVR  
RANDOM 
EFFECTS  
PROBABILITY  
BEST % 
REDUCING 
THROMBOSIS 
FIXED 
EFFECTS 
    0 
BMS    0.9 0 0 0 
SIROLIMUS    0.98   1.5 6.1      0.5 
EVEROLIMUS    5.9  39.2 11.1 82 
PACLITAXEL    5.9 0 0 0 
ZOTAROLIMUS 10   11.6 0      2.3 
BIOLIMUS      9.4     1.3    12      2.5 
ZOTAROLIMUS RESOLUTE     66.7 46 70    12 
     
 
   
 
Table 4
Table 5. Odds Ratio Short Term  
 Comparator CARDIAC 
DEATH 
ODDs 
RATIO  
FIXED 
EFFECTS 
97.5% CI MI 
ODDS 
RATIO 
FIXED 
EFFECTS 
97.5% 
CI 
Comparator TVR ODDs 
RATIO 
RANDOM 
EFFECTS 
97.5% CI THROMBOSIS 
ODDS RATIO  
FIXED EFFECTS 
97.5% CI 
BMS           
 SIROLIMUS 0.95 0.72-1.23 0.74* 0.60-
0.90* 
SIROLIMUS 0.28* 0.22-0.36* 0.79 0.57-1.08 
 EVEROLIMUS 0.85 0.61-1.16 0.62* 0.48-
0.79* 
EVEROLIMUS 0.27* 0.18-0.36* 0.53 0.34-0.77* 
 PACLITAXEL 0.9 0.66-1.20 0.92 0.75-1.12 PACLITAXEL 0.45* 0.34-0.58* 1.00 0.67-1.44 
 ZOTAROLIMUS   1.03 0.55-1.75 0.73* 0.54-
0.96* 
ZOTAROLIMUS 0.44* 0.29-0.61* 0.99 0.48-1.82 
 BIOLIMUS 0.89 0.60-1.27 0.79 0.58-1.04 BIOLIMUS 0.29* 0.18- 0.42* 0.76 0.47-1.19 
 RESOLUTE    0.69   0.35-1.22   0.63*   0.45-
0.85* 
RESOLUTE    0.22*   0.11-0.38*   0.71   0.32-1.36 
SIROLIMUS           
 EVEROLIMUS 0.90 0.68-1.17 0.84 0.68-1.03 EVEROLIMUS 0.94 0.69-1.24 0.67 0.46-0.93* 
 PACLITAXEL 0.94 0.72-1.22 1.24 1.05-1.47 PACLITAXEL 1.59* 1.27-1.97* 1.29 0.87-1.81 
 ZOTAROLIMUS 1.08 0.59-1.81 0.98 0.75-1.25 ZOTAROLIMUS 1.53* 1.10-2.09* 1.27 0.61-2.27 
 BIOLIMUS 0.94 0.66-1.29 1.06 0.83-1.35 BIOLIMUS 1.01 0.68 -1.42 0.97 0.63-1.43 
 RESOLUTE  0.73 0.38-1.26
 
0.85 0.62-1.12 RESOLUTE  0.78 0.41 -1.32 0.90 0.42-1.65 
EVEROLIMUS           
 PACLITAXEL 1.06 0.76-1.44 1.48* 1.20-1.8* PACLITAXEL 1.71* 1.27-2.28* 1.94 1.28-2.81*
 
 ZOTAROLIMUS 1.22 0.64-2.11 1.17 0.85-1.55 ZOTAROLIMUS 1.65* 1.08-2.45* 1.92  0.90-3.56 
 BIOLIMUS 1.05 0.73-1.46 1.26 0.99-1.60 BIOLIMUS 1.08 0.72 -1.56 1.47 0.93-2.25 
 RESOLUTE  0.81 0.45-1.33 1 0.80-1.23 RESOLUTE  0.83 0.46-1.35 1.34 0.69-2.35 
           
PACLITAXEL           
 ZOTAROLIMUS 1.15 0.64-1.91 0.79* 0.61-
1.00* 
ZOTAROLIMUS 0.96 0.68-1.33 0.99 0.51-1.75 
 BIOLIMUS 1.00 0.66-1.46 0.85 0.65-1.11 BIOLIMUS 0.63* 0.42-0.92* 0.77 0.46-1.25 
 RESOLUTE  0.78 0.40-1.37 0.68 0.50-
0.90* 
RESOLUTE  0.49* 0.26-0.82* 0.71 0.33-1.35 
           
ZOTAROLIMUS           
 BIOLIMUS 0.93 0.47-1.66 1.10 0.77-1.52 BIOLIMUS 0.67 0.40-1.04 0.85 0.38-1.7 
 RESOLUTE  0.72 0.30-1.48 0.87 0.60-1.24 RESOLUTE  0.52* 0.25-0.93* 0.79   0.28-1.74 
BIOLIMUS           
 RESOLUTE 0.79 0.39-1.41 0.80 0.57-1.09 RESOLUTE 0.79 0.39-1.42 0.95 0.42-1.83 
Median estimate of heterogeneity  NA  NA   0.34 0.20-0.50 NA  
Table 5
  
* Evidence of a significant effect  
 
 ( 95% CrI) 
           
Table 6. Included Studies 
 
Study Year  Comparative 
Arms  
Sex  Age  
BASKET [50]  2005 SES (n=264), 
PES 
 (n=281), 
 BMS (n=281) 
Male 
(79%)  
Male (79%) 
 
 
Age (years) 64±11 Age 
(years) 64±12 
CATOS[51] 2012 ZES (n=80 ) 
SES  (n=80), 
Male (65%) 
Male (76%) 
Age (years) 62.7±12.3 
Age (years) 63.0±11.7 
C-SIRIUS[52]  
2004 
SES(n = 50), 
BMS(n =50) 
Male (70 %)  
Male (68%) 
Age (years) 60.3 ±10.6, 
 Age (years) 60.7± 9.1, 
CHEVALIER [53] 2007 BES 
(n=85),PES 
(n=35) 
 Male (69 %) 
Male (66%) 
Age (years) 65±11, Age 
(years) 63±11 
COMFORTABLE AMI[54] 2012 BES (n = 575) 
BMS(n = 582), 
 Male  
(80.5%), 
Male  
(78.2%) 
 
Age ,(years) 60.7±  
11.6, Age, (years), 60.4 
± 11.9 
COMPARE [55] 2010  EES(n=897), 
PES (n=903)  
Male (69%),  
Male 
 (72%) 
Age (years)62.9 ± 
15.7,Age (years) 
63.6±17.2  
COMPARE II[56] 2013 BES(n=1795) 
EES(n=912) 
Male 
(74?4%), 
Male(74.3%) 
Age (years) 63± 11.1, 
Age (years) 62.7± 11.0 
DEBATER[57] 2 0 1 
2 
SES (n =424) 
BMS (n = 446 
Abciximab(n = 
439) , No 
Abciximab (n 
= 434) 
Male  (78%), 
Male (75%), 
Male  (76%) 
Male (78%) 
Age(years) 60±11 Age 
(years) 61±11 Age 
(years) 60±10 , Age, 
(years)60±12 
DESSERT[58]  2008 SES(n = 75) 
 BMS (n = 75) 
Male(63%), 
Malen(49%) 
Age (years) 71 ±9 Age 
(years) 69±9, 
DIABEDES[59] 2007 SES(n = 76) 
PES(n =77) 
Male  (84%) 
 Male (74%), 
Age (years) 66 ±8, Age 
(years) 65 ±10 
DIABETES[60] 2005 SES (n = 80) 
 BMS (n = 80) 
Male (70%) 
Male  (81%) 
Age (years)  
65.9±9 6 
Age (years) 
7.2±10 
DIAS DE LA LIERA[61] 2007 BMS 
(n = 54),  
SES 
(n = 60) 
Male  
(78.3%) , 
Male (80.0) 
Age, (years)  65 ±13 64  
DIBRA[62] 2005 BMS(N=125), 
SES(N=125), 
Male (64%), 
Male (68%) 
Age (years) 68.3±9.6 
Age (years) 67.7±10.2 
 
E-SIRIUS[63] 2003 SES (n=175), 
BMS (n=177), 
Men (70%), 
Men 126 
(71%), 
Age (years) 62·0 ±11·4,  
age (years)62·6±10·3, 
ENDEAVOR II[64] 2006 EES(n=598), Male (77%), Age(years)61.6±10.5, 
Table 6
BMS (n=599) Male  (75%) Age (years) ,61.9±10.5 
ENDEAVOR III[65] 2006 ZES(n=323), 
SES (n=113)  
 
Male  
(65.3 %)  
Male 
 (81.4 %)  
 
Age (years) 61.42 
±10.58, 
Age (years) 61.73 
±11.59  
 
ENDEAVOR IV [66] 2010 ZES  (n =773) 
 PES (n =775), 
Men 
(66.9%) 
Men 
(68.5%)  
Age, (years) 63.5± 11.1  
Age( years )63.6 ± 11.0 
ESSENCE DIABETES[67] 2013 EES(n=149) 
SES(n=151) 
Men 
(52.3%) 
,Men 
(65.6%)  
Age (years) 63.2±8.3, 
Age (years )63.5±8.1 
EXCELLENT[68] 2011 EES (n = 
1,079), SES (n 
= 364) 
Male  
(65.2%) 
Male  
(62.6%) 
 
Age (years) 62.5 ±10.1 
Age (years) 63.4  ±9.9 
 
Erglis[69]
 
 2007 BMS (n =50) ), 
PES (n = 53)  
 
Male (82%) 
Male (85%) 
Age  (years) 62.56  
±11.45,  Age(years) 
61.08± 10.28,   
HORIZON AMI STONE 
[70] 
2009 PES(N = 
2257)  
 BMS (N = 
749)  
 
Male . 
(77.0%), 
Male 
(76.0%) 
 
Age (years) 59.9  
Age (years)  59.3 
 
LEE [71] 2008 SES(n = 200), 
PES 
(n =200) 
 
 
Men 
(61.0%) 
Men(55.0%) 
Age (years) 61.1± 8.9 , 
Age (years), 60.7  ±8.8 
EUROSTAR[72] 2011 PES (n=152) 
BMS (n=151) 
Male 
(74.3%),  
Male  
(68.9%) 
Age (years) 64.9±9.2, 
Age (years) 66.2±9.4 
 
EXAMINATION [73] 2012 EES (n=751 
BMS (n=747)  
 
Male (82%) 
Male  (84%),  
 
Age (years), 
60±8  
Age (years),   
61±6  
 
ISAR LEFT MAIN[74] 2009 PES (n = 302)  
SES (n = 305)  
 
Μale (23%), 
Male (38%) 
Age, (years) 68.8± 10.1 
Age, (years) 69.3  ± 
9.34,  
 
JUWANA [75] 2009 SES(n = 196)  
PES(n=201)  
 
Men (69%),  
Men(74%) 
 
Age (years)  
61± 11,  
 
KIM [76] 2008 SES  
(n = 85),  
PES (n = 84) 
Male  
(71.8%), 
Male  
(76.2%) 
Age (years) 62.9 ± 8.0 , 
Age (years) 61.5 ± 8.9 
LEADERS[77]  2008 BES (n=857)  
SES(n=850)  
Men 
 (75%),  
Age (years) 64.6 ±10.8,  
Age (years) 64.5 ±10.7 
 Men  (74%) 
 
 
LONG DES II[78] 2006 SES (n=250)  
PES(n=250)  
 
Male  
(67.2%) 
Male 
(61.2%) 
 
Age (years)61.4 
Age (years) 60.7 
 
LONG DES III[79] 2 0 1 
1 
EES (n = 224)  
SES(n =226)  
 
Male 
(73.7%),  
Male(65.9%) 
 
Age, (years) 62.9 
Age, (years) 63.0 
 
LONG DES IV[80] 2012 RESOLUTE-
ZES (n= 250) 
SES (n=250 )  
 
Male , 
(73.6%)  
Male, 
(72.4%) 
 
Age (years)62.8±9.7, 
Age,(years)62.7±9.8,  
 
LIPSIA[81] 2 0 1 
1 
SES(n= 120)  
PES(n= 
116)  
 
Male (69%),  
Male (68%) 
 
Age(years) ,67.0±9.5 
Age (years), 67.3±9.1,  
 
MISSION [82] 2008 SES (n = 158)  
BMS (n = 152) 
 
Male (69%),  
Male (68%) 
 
Age (years) 59.2   
Age (years) 59.1  
 
MULTISTRATEGY[83] 2008 Abciximab 
Plus BMS(n = 
186)  
Abciximab 
Plus (n = 186)  
Tirofiban Plus 
BMS (n = 186)  
Tirofiban Plus 
SES(n = 186)  
 
Male 
(73.1%),  
Male  
(72.6%),  
Male 
(79.5%),  
Male 
(78.5%) 
 
Age, (years) 63.9 
±11.7,  
Age, (years) 62.7± 11.2  
Age, (years) ,65.4 
±12.1 
Age,(years),63.4±12,  
 
Natsuaki [84] 2013 BES (n=1617) 
EES (n=1618) 
Male  (77%), 
Male (77%) 
Age (years) 69.1±9.8,  
Age  (years) 69.3±9.8,  
PACHE MEHILI [85] 2005  PES (n= 250) 
BMS(n = 250) 
Men (78%) 
Men (78%) 
Age (years ) , 
67.4±16.4 
Age, (years) 66.7 ± 
14.8 
PAINT[86] 2009 PES (n =111)  
BMS(n = 57)  
SES(n = 106)  
 
Men (61.3 
%) 
Men 
(67.0%) 
Men 
(66.7%),  
 
Age, (years) 60.1  
 ± 10.2 
Age, (years)59.7 ±10.6,  
Age, (years)58.5 ± 9.6 
 
PROSIT[87] 2008 SES (n=  154) 
PES (n = 154) 
Male 
(76.0%) 
Male(76.6%) 
Age (years) 60 .6 ±11 
Age(years),60 .6 ±12 
NOBORI[88] 2011 BES(n  
=194)  
SES(n =132)  
 
Male 
(71.6%),  
Male  
(72.0%) 
 
Age (years) 67.1 ± 10.3 
Age (years)67.7 ± 9.3,  
 
PAN[89] 2012 SES(n = 145)  
EES(n = 148) 
 
Male (79%) 
Male  
 (82%),  
 
Age (years) 63  ±  10 
Age (years) 63 ±  11 
 
RAVEL[90] 2002 SES 
(n=120)  
BMS (n=118)  
 
Male  (70%),  
Male (81%) 
 
Age (years) 61.8±10.7, 
Age (years) 59.7±10.1,  
 
REALITY[91] 2006 SES(n = 684)  
PES(n = 669)  
 
Men 
(72.0%) 
, Men  
(74.1%) 
 
Age 
(years) 62.6 ±10.5,  
Age 
(years) 62.6 ± 
10.0,  
 
REMEDEE[92] 2 0 1 
3 
SES(n = 124)  
PES(n=59)  
 
Men 
(71.8%), 
Men(71.2%) 
 
Age (years) 64.20 
±9.48 
Age (years) 64.05 ± 
10.49 
 
RESET[93] 
 
2013 SES (n=1600) 
EES (n=1597 ) 
 
Male 
(12.17%), 
Men(76%) 
Age(years) 68.9±9.7, 
Age (years) 69.3±9.6,  
 
RESOLUTE[94] 2 0 1 
3 
RESOLUTE 
ZES(n=198)  
PES(n = 202)  
 
Male  
(77.8%),  
Male  
(80.7% ) 
 
Age, (years) 59.7±9.9,  
Age, (years)59.6±10.6,  
 
SEPARHAM [95] 2011 BES (n=100) 
EES (n=100) 
 
Male (66%) 
Male (64%) 
Age, (yrs)60.60±9.1, 
Age, (yrs) 62.38±10.2 
SESAMI [96] 2007 SES (n = 160)  
BMS (n = 160)  
 
Male  (80%),  
Male  (80%),  
 
Age (years) 63±20, 
Age (years) 62 ±16 
 
 
SEZE[97] 2012 ZES  
(n=60)  
SES (n=61)  
 
Male 
(81.6%) 
Male ( 
80.3%)  
 
 Age (years) 59.8±13.3  
Age (years)  
62.0±11.5  
 
SERRYUS[98] 2010 ZES (N = 
1152)    
EES (N = 
1140)   
 
Male 
(76.7%),  
Male 
(77.2%),  
 
 Age ( years)    
64.2±10.8 
Age( years)  64.4±10.9 
 
SORT OUT  IV[99] 2012 SESn=1384 
EES n=1390 
Men 
(75.5%), 
Men  
(72.4%). 
 
Age (years) 64.1± 10.8,  
Age(years)  63.5 ±13.2,  
 
SORT OUT  V [100] 2013 BES(n=1229)  
SES(n=1239)  
 
Men 
(74·6%), 
Men 
(75·1%) 
 
Age  
(years) 65·0 ±10·6,  
Age (years) 65·2 ±10·3,  
 
SPIRIT III STONE [101] 2008 EES  (n=669) 
PES (n= 
332) 
Men  
 (70.1%),  
Men 
(10.2%) 
 
Age,  (years) 63.2± 
10.5,  
Age (years) 62.8 ±10.2,  
 
SPIRIT IV [102]  2013 EES 
(n = 2458) 
PES 
(n = 1229 ) 
Male  
(67.7%),  
Male 
(67.8%) 
 
Age (years) 63.3±10.5 
Age  (years) 63.3±10.2 
 
SPIRIT V [103]  EES(n = 218)  
PES(n = 106)  
 
Male (70 %) 
Male (67% ) 
Age (years) 65 ± 10 
Age (years) 66 ±  
9,  
 
STEALTH[104] 
 
2005 BES (n=80)  
BMS (n=40) 
Male  (48%),  
Male  (33%) 
 
Age 
(years) , 62.2 ± 10.1 
Age (years) , 61.1 ± 
9.4,  
 
ZEST AMI [105] 2009 ZES n=( 108) 
SES 
(n = 110) 
PES 
(n =110) 
Male 
(77.8%) 
Male  
(86.4%) 
Male  
(82.7%) 
Age, (years) 61.9  ± 
11.0, Age (years),  57.8 
± 11.3 Age (years) , 
59.3  ±  11.2 
TAXI [106] 2005 PES (n = 100)  
SES(n = 102)  
 
 
Male(83%) 
Male 
(79/%),  
 
 Age (years) 63 ± 10 
 Age (years) 65± 10 
 
TAXUS VI[107] 2005 PES 
(n = 577)  
, BMS (n = 
579)  
 
Male 
(70.2%),  
Male 
(68.7%) 
 
Αge  (years) 62.9 ± 
11.2,  
Age,   
(years) 62.8 ±10.8,  
 
TAXUS[108] 2005 PES (n=219)  
BMS(n=227),  
 
Male,   
(76.3%)  
Male,  
(76.2%)  
 
Age (years )61.8±9.7,  
Age (years) 63.4±9.9,  
 
TYPHHON [109] 2006 SES(N = 355)  
BMS(N = 357)  
 
Male 
(78.6%),  
Male 
(78.2%),  
 
Age  (years) 58.0,  
Age (years)  60.5,  
 
TWENTE[110] 2012 
 
 RESOLUTE 
ZES  
(n =697), EES  
(n=694) 
Men 
(72.5%), 
Men 
(72.6%) 
Age (years) 64.2 ± 10.8 
, Age (years) 63.9±  
10.9, Age  (years) 64.5 
±  10.7  
XAMI[111] 2012, EES (n=404)  
SES (n = 221)  
 
Male  
(73.0%)  
Male 
(75.1%)  
Age (years) 61.2 ± 
11.3,  
Age (years) 62.0± 11.4 
 
 
ZEST[112] 2010 ZES (n=883) 
SES (n =878) 
PES (n=884)  
 
Male 
(66.4%), 
Male  
(67.3%), 
Male  
(65.8%) 
 
Age, (years) 61.7±  9.3,  
Age, (years) 61.9  ±9.6 
Age, (years) 62.0 ± 9.6,  
 
ZOMAXX[113] 2011 ZES(n=557) 
PES(n=542),  
 
Male ( 69%),  
Male ( 69%) 
 
Age (years) 63±10 
Age (years) 63±11 
 
 
     
BASKET  PROVE KAISER 
[114] 
2013 EES (n=774)  
SES (n=775) 
BMS (n=774)  
Male(76%)Mal
e(74%) 
Male(77%) 
Αge(years) 
66±11 
 Age 
(years)66±1
1  
Age (years) 
67±11 
Byrne[115] 2010 SES (n = 335), 
ZES (n = 339). 
Male (77.3%)  
Male (75.5%) 
Age (years ) 
66.6±11.1 
Age 
(years)67.2 
±10.9 
COMPARE[116] 2011  
EES 
(n = 897) 
PES 
(n = 903) 
 
Male(69%) 
Male (72%) 
 
Age 
(years)62.9 
± 15.7,Age 
(years) 
63.6±17.2 
DES DIABETES[117] 2011 SRL( n=200) 
PES(n =200) 
Male (61%) 
Male (55%) 
Age (years) 
61.1±8.9 
Age 
(years)60.7±
8.8, 
ENDEAVOR II FIVE 
YEARS[118] 
2010 ZES(n= 598),  
BMS(n =599) 
Male(77.2%)  
Male (75.4%) 
Age, (years)  
61.6±10.5  
Age, (years) 
61.9±10.5 
ENDEAVOR III 5 YEARS 
[119] 
2011 ZES (n = 323), 
SES (n=113) 
Male(65.3% ) 
Male(81.4%) 
Age (years), 
61.42±10.58 
Age (years), 
61.73±11.59
,  
 
ENDEAVOR IV[120] 2013 ZES(n= 773)  
PES(n= 775)   
Male(66.9%) 
Male(68.5%) 
Age, (years 
)63.5±11.1  
Age, (years 
)63.6±11.0 
GISSOC [121] 2010  BMS(n = 78) 
SES(n = 74) 
Male  (87.1%), 
Male (78.3%) 
 
Age (years) 
63.9±9.8, 
Age 
(years)63.9±
9.6, 
HONG[122] 2010 SES  (n =85) 
PES  (n =84) 
Male (71.8%) 
Male (76.2%) 
Age (years) 
65.9±  8.0, 
,Age (years) 
64.5±  8.9,  
 
HORIZON AMI[123] 2011 Heparin plus a 
GPI(n=1802), 
Bivalirudin 
monotherapy(n
=1800) 
PES(n=2257), 
BMS(n=749)  
 
Male (76%) 
Male (77%), 
Male (76%) 
Age (years) 
60.7± 17.2 
Age (years) 
59.8±17.6   
Age (years) 
59.9±17, 
Age (years) 
59.3±17.4  
ISAR LEFT MAIN [124] 2009  
PES (n = 302) 
SES (n = 305) 
Male(75%) 
Male(80%) 
 
Age, (years)  
68.8 ± 10.1 
Age (years) 
69.3 ±9.34  
 
Klaus [125] 2011  BES (n = 
857),  
SES (n = 850),  
 
Male (75%) 
Male (74.6%) 
Age, (years) 
64.6±10.8 
Age, (years) 
64.5±10.7 
KOMER[126] 2011 ZES (n=205) 
SES (n=204) 
PES (n=202) 
Male(76%) 
Male(81%) 
Male(79%) 
Age, (years) 
60±13  Age 
(years), 
59±12,  
Age(years) 
,60±13,  
Leaders [127] 2011 BES(n= 857) , 
SES(n= 850)  
Men 
 (75%),  
Men  (74%) 
 
Age (years) 
64.6 ±10.8,  
Age (years) 
64.5 ±10.7 
 
LATE [128] 2011 SES (n=503), 
PES(n= 509)  
Male(76%), 
Male(78%) 
Age (years) 
62±11   
Age (years) 
62±12 
MISSION [129] 2012 SES (n=158) 
BMS (n=152 
Men (74.7%) 
Male(80.9%) 
 
Age (yrs)  
59.2±11.2  
Age (yrs)  
59.1±11.6 
 
NAPLES DIABETES [130] 2011 SES (n=76) 
PES  (n=75), 
EES 
 (n=75) 
Male (57%),  
Male (59%) ,  
Male (56%) 
 
Age, (years) 
64±8, Age, 
(years) 
64±10 Age, 
(years) 
65±8, 
MULTISTRATEGY [131] 2013 SRL(n=  370) 
BMS(n=372) 
Male (73.1%) 
Male (72.6%)  
Age 
(years)63.9 
±11.7 
Age (years) 
62.7 ± 11.2 
Age (years)  
65.4 ±12.1 
  Age 
(years) 63.4 
±12 
PAINT [132] 2012 PES (n=111) 
SES (n=106)  
BMS(n=57) 
 
Male(61.3 %) 
Male(67.0%) 
Male(66.7%) 
Age, (years) 
60.1±10.2 
Age (years) 
59.7±10.6 
Age (years) 
58.5±9.6 
PASEO [133] 2009 BMS (n = 90 ) 
PES (n =90) 
Male(71.1% ) 
Male(68.9%) 
Age, (years) 
62± 17,  
Age (years) 
63± 15 
 
PASSION [134] 2011 PES(n=  310) 
BMS 
(n = 309) 
Male(73.9%) 
Male(78%) 
Age, (years) 
61±12, 
 Age, 
(years) 
61±13 
 
PRISON[135] 2012 BMS(n=100) 
SES (n=100) 
 
Male (76%)  
Male(83%) 
Age (years) 
59.3±10.2 
Age (years) 
59.6±10.6  
 
PROTECT [136] 2012 EES (n=4357) 
SES (n=4352) 
Male(77%) 
Male (76%) 
Age (years) 
62·3 ±10·6,  
Age (years) 
62·1± 10·7 
PROSIT  [137] 2011 SES (n = 154) 
PES (n = 154) 
Male(76%) 
Male(76.6%) 
Age (years), 
60 .6 ±11,  
Age (years), 
60. 6 ±12 
PURICEL [138] 2013 ERL(n= 200) 
BES(n= 200) 
Male(75.5%) 
Male( 73%) 
Age (years ) 
65.9±11.2  
 Age (years) 
64.9±10. 
 
RAVEL [139] 2007 SES(n= 120) 
BMS (n=118) 
Male(70%/ ) 
Male(81%) 
Age (years) 
61.8±10.7 
Age (years) 
59.7±10.1 
 
RESOLUTE[140] 2011 RESOLUTE -
ZES(N=1140) 
EES(N=1152) 
Male(76.7%)  
Male(77.2%) 
Age (years) 
64·4 ± 10·9, 
Age (years) 
64·2 ± 10·8 
 
 SCOPRIUS[141] 2012 SES (n = 95) 
BMS (n = 95) 
Male(66%) 
Male(62%)  
Age (years) 
66 ± 9,  
Age (years) 
66 ± 10 
 
SEASIDE [142] 2011 SES (n= 75)  
ERL (n= 75) 
Male(75%) 
Male(85%) 
Age, (years) 
64±10  
SESAMI[143] 2011 SES( n=155 ) 
BMS (n=155)  
Male(82%) 
Male(81%) 
Age, (years) 
63±15,  
Age (years) 
63± 19 
SIRTAX [144] 2008 SES(n= 503)  
PES (n = 509 ) 
Males (69.4%)  
Male(72.0%) 
Male (79.8%) 
 
Age (years) 
62 ± 10 
SORT OUT III 18 MONTHS 
[145] 
2010 ZES (n = 1,162) 
SES 
(n =1,170) 
 
Male(73% ) 
Male(74%)  
Age(years), 
64.3± 10.7 
Age (years), 
64.3± 10.8 
 
SORT OUT III[146] 2012  ZES (n = 1,162) 
 
SES 
(n = 1,170) 
 
Male(73% ) 
Male(74%)  
Age, (years) 
64.3± 10.7, 
Age (years) 
64.3±10.8 
 
SORT OUT IV [147] 2012 EES 
(n=1390), 
 
SES 
(n=1384), 
 
 
Male(75.9% ) 
Male(75.2% ) 
Age years , 
64.2 ±10.9, 
Age  years, 
64.0±10.8 
SPIRIT II 3 YEARS [148] 2009 EES 
(n = 223) 
PES 
(n = 77) 
 
Male(71%) 
Male(79%) 
Age (years) 
62±10, Age 
(years) 62±9  
 
 TAXI LATE [149] 2007  SES(n= 100) 
PES (n= 102) 
Male(77%), 
Male(83%) 
Age (years), 
65. 6±10, 
Age (years) 
,63. 6± 10 
TAXUS [150] 2011 BMS (n=1397) 
PES (n=1400) 
Age (81,7%) 
Age (71.5%) 
Age (years), 
62.2±10.7  
Age (years), 
62.8±11.0 
TAXUS IV[151] 2009  
BMS (n=643) 
PES (n = 651 
Male (72.2%) 
Male(71.7%) 
 
Age (years) 
62.1±11.0  
Age  (years) 
62.8±11.2 
TAXUS VI[152] 2009 BMS (n=233 ) 
PES(n =217) 
Male (70.2%),  
Male (68.7%) 
 
Αge  (years) 
62.9 ± 11.2,  
Age,   
(years) 62.8 
±10.8,  
 
TWENTE[153] 2013  Resolute- ZES 
(n= 697) 
EES(n= 694) 
 
Men  (72.5%) 
Men (72.6%) 
 
Age (years) 
63.9 ± 10.9,  
Age (years) 
64.5 ± 10.7 
 
Typhoon[154] 2011 SES (n=355) 
BMS (n=357) 
Male (77.7%) 
Male(78.6%) 
Age, (years) 
59.3±13.2 
Age, (years) 
59.2±11.7, 
ZOMAXX[155] 2013 ZES 
(n=199) 
PES 
(n=197) 
Male (75%) 
Male(77%) 
 
Age (years) 
63 ± 10  
Age (years) 
63 ± 11  
 
     
 
